View Document Preview and Link Open Document File Size: 2,00 MB Share Result on Facebook
Company Pixantrone Cell Therapeutics Inc. / Cell Therapeutics Inc / International Working Group / / Country United States / India / / Event FDA Phase / / Facility Cornell Weill Medical Center / / IndustryTerm pivotal study protocol / / MedicalCondition cancer / Relapsed/Refractory Aggressive NHL Non-Hodgkin’s lymphomas / disease / large B-cell lymphoma / Ann Arbor stage III/IV disease / refractory aggressive NHL Disease / superior disease / refractory aggressive Non-Hodgkin’s Lymphoma / / MedicalTreatment stem cell therapy / chemotherapy / radioimmunotherapy / immunotherapy / / Organization Division of Oncologic Drug Products / Data Monitoring Committee / Independent Assessment Panel / Cornell / FDA / Oncologic Drugs Advisory Committee / Cornell Weill Medical Center / / Position investigator / pathologist / EXECUTIVE / physician / Fisher / representative / representative of US histologic subtypes / / Product etoposide / cytarabine / ifosfamide / mitoxantrone / PIX301 / PIXUVRI™ (pixantrone dimaleate) injection / Oncologic Drug / / ProvinceOrState Washington / / Region Latin America / Eastern Europe / Western Europe / / SportsEvent NHL / / Technology cell therapy / pivotal study protocol / chemotherapy / / SocialTag 
Oncologic Drugs Advisory Committee Meeting Briefing Document Pixantrone dimaleate (BBR[removed]Injection for the treatment of patients with relapsed or refractory aggressive Non-Hodgkin’s Lymphoma who have received 2 or